Molecular targets of cannabinoids and their derivatives in epilepsy – a review with focus on CBD
Abstract In recent years, cannabinoids and their derivatives have been tested for efficacy in epilepsy therapy and related disorders. Many…
cannabidavarin (CBDV)
Therapeutic Potential of Minor Cannabinoids in Dermatological Diseases—A Synthetic Review
Abstract Dermatological diseases pose a significant burden on the quality of life of individuals and can be challenging to treat…
Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial
Abstract Objective: Rett syndrome (RTT), commonly caused by methyl‐CpG‐binding protein 2 (MECP2) pathogenic variants, has many comorbidities. Fifty to ninety…
Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin
Abstract Background: Autism spectrum disorder (ASD) has a high cost to affected individuals and society, but treatments for core symptoms…
Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances
Abstract Epilepsy is a neurological disorder mainly characterised by recurrent seizures that affect the entire population diagnosed with the condition.…
Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review
Abstract Human immunodeficiency virus (HIV) infection and antiretroviral therapy can independently induce HIV-associated neuropathic pain (HIV-NP). There is a dearth…
Structure–Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives
Abstract Background: As a library of cannabinoid (CB) derivatives with (-)-trans-cannabidiol (CBD) or (-)-trans-cannabidivarin (CBDV) scaffold, we synthesized nine novel…
Low doses of widely consumed cannabinoids (cannabidiol and cannabidivarin) cause DNA damage and chromosomal aberrations in human-derived cells
Abstract Electronic supplementary material: The online version of this article (10.1007/s00204-018-2322-9) contains supplementary material, which is available to authorized users.…